Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 14/20 | 0.44 |
| ▸ | HTR2C | P28335 | 14/20 | 0.44 |
| ▸ | HTR2B | P41595 | 14/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8063906 | 1.00 | HTR2A (0.44) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL17559139 | 1.00 | HTR2A (0.44) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL7954422 | 1.00 | HTR2A (0.44) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL9772360 | 1.00 | HTR2A (0.44) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL7764372 | 0.82 | SLC6A2 (0.37) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL5730688 | 0.82 | HTR2A (0.40) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL2444502 | 0.81 | KCNE1 (0.37) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL30832970 | 0.81 | KCNE1 (0.37) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL7761032 | 0.80 | SIGMAR1 (0.48) | SIGMAR1 | |
| SCHEMBL9772397 | 0.79 | SLC18A3 (0.50) | HTR2AHTR2CHTR2BHRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046515-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2019-02-14 | — | — | US | disclosed |
| US-20190046515-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2019-02-14 | — | — | US | disclosed |
| US-10130619-B2 | Amido thiadiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-11-20 | — | — | US | disclosed |
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2017-12-07 | — | — | US | disclosed |
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2017-12-07 | — | — | US | disclosed |
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2017-12-07 | — | — | US | disclosed |
| WO-2016098005-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-06-23 | — | — | WO | disclosed |
| EP-3034500-A1 | Amido thiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| EP-3034500-A1 | Amido thiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2016-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX5, CYBB | HTR2A 4176/4885HTR2C 3798/4885HTR2B 3178/4885 |
| US-20190046515-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX5, CYBB | HTR2A 4176/4885HTR2C 3798/4885HTR2B 3178/4885 |
| US-10130619-B2 | Amido thiadiazole derivatives as NADPH oxidase inhibitors | NOX1, NOX5, CYBB | HTR2A 4176/4885HTR2C 3798/4885HTR2B 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.